Pulmonary Arterial Hypertension Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Pulmonary Arterial Hypertension stocks.

Pulmonary Arterial Hypertension Stocks Recent News

Date Stock Title
May 6 UTHR United Therapeutics Corporation (UTHR) Hits Fresh High: Is There Still Room to Run?
May 4 ASND Ascendis Pharma A/S (ASND) Q1 2024 Earnings Call Transcript
May 4 ASND Ascendis Pharma First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
May 4 GILD 23 Most Profitable Stocks of the Last 12 Months
May 3 UTHR 30 Most Profitable Companies with Highest Margins in the World
May 3 GILD Forbes Has Listed Gilead as One of America’s Best Employers for Diversity
May 3 KROS Keros Therapeutics files automatic mixed shelf
May 3 GILD The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine
May 2 ASND Ascendis Pharma reports Q1 results
May 2 ASND Ascendis Pharma Reports First Quarter 2024 Financial Results
May 2 UTHR United Therapeutics (UTHR) Q1 Earnings Top, Tyvaso Drives Sales
May 2 UTHR United Therapeutics Corporation (NASDAQ:UTHR) Q1 2024 Earnings Call Transcript
May 2 GILD Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More
May 2 UTHR United Therapeutics Corp (UTHR) Q1 2024 Earnings Call Transcript Highlights: Record Revenue and ...
May 2 UTHR Q1 2024 United Therapeutics Corp Earnings Call
May 1 ASND Ascendis Pharma Q1 2024 Earnings Preview
May 1 UTHR Lung Disease-Focused United Therapeutics Says It Is A Compelling Investment Opportunity
May 1 UTHR United Therapeutics Corporation (UTHR) Q1 2024 Earnings Call Transcript
May 1 UTHR Compared to Estimates, United Therapeutics (UTHR) Q1 Earnings: A Look at Key Metrics
May 1 UTHR United Therapeutics Surpasses Analyst Revenue Forecasts with Strong Q1 2024 Performance
Pulmonary Arterial Hypertension

Pulmonary hypertension (PH or PHTN) is a condition of increased blood pressure within the arteries of the lungs. Symptoms include shortness of breath, syncope, tiredness, chest pain, swelling of the legs, and a fast heartbeat. The condition may make it difficult to exercise. Onset is typically gradual.The cause is often unknown. Risk factors include a family history, prior blood clots in the lungs, HIV/AIDS, sickle cell disease, cocaine use, COPD, sleep apnea, living at high altitudes, and problems with the mitral valve. The underlying mechanism typically involves inflammation of the arteries in the lungs. Diagnosis involves first ruling out other potential causes.There is no cure. Treatment depends on the type of disease. A number of supportive measures such as oxygen therapy, diuretics, and medications to inhibit clotting may be used. Medications specifically for the condition include epoprostenol, treprostinil, iloprost, bosentan, ambrisentan, macitentan, and sildenafil. A lung transplant may be an option in certain cases.While the exact frequency of the condition is unknown, it is estimated that about 1,000 new cases occur a year in the United States. Females are more often affected than males. Onset is typically between 20 and 60 years of age. It was first identified by Ernst von Romberg in 1891.

Browse All Tags